市場調查報告書
商品編碼
1468062
2024-2032 年按放射性核種類型、醫療應用、最終用戶和地區分類的α發射體市場報告Alpha Emitter Market Report by Type of Radionuclide, Medical Application, End User, and Region 2024-2032 |
IMARC Group年全球α輻射體市場規模達14.768億美元。
阿爾法發射體是放射源發射的物質,在釋放阿爾法粒子後會衰變。它們實現適當的生物分佈和相關的劑量分佈,以實現有效的治療,而不會引起不可接受的急性或長期副作用。 α粒子具有極高的細胞殺傷率,在醫療過程中使用時比BETA粒子對腫瘤細胞更具破壞性。因此,它們對鄰近正常組織造成的損害較小。鐳、鉛和鉍是治療過程中使用的一些放射性核種。 α粒子的短程和高線性能量轉移(LET)使其對醫學研究非常有吸引力,特別是作為一種可行的癌症治療方法。有多種類型的癌症可以用α發射體治療,包括卵巢癌、胰臟癌、淋巴瘤和黑色素瘤。
該市場主要由癌症治療領域進行的廣泛高階研發(R&D)活動所推動。這可以歸因於人們對目標α發射體的細胞殺傷能力的認知不斷增強。與此一致的是,大眾中各種類型癌症的盛行率不斷上升,為市場提供了動力。此外,容易患多種心臟病和癌症疾病的老年人口不斷增加,也為市場創造了積極的前景。此外,醫療機構擴大採用標靶抗癌或阿爾法療法(TAT),正在對市場產生積極影響。持續的技術進步和越來越多的新核醫學產品批准進一步推動了市場。影響市場的其他一些因素包括快速城市化、醫療基礎設施的不斷改善、醫療支出的增加以及個人可支配收入水準的提高。
The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032.
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha emitter market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type of radionuclide, medical application, and end user.
Astatine
Radium
Actinium
Lead
Bismuth
Others
Prostate Cancer
Bone Metastasis
Ovarian Cancer
Pancreatic Cancer
Endocrine Tumors
Others
Hospitals
Medical Research Institutions
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.